clinical trial · NCT05364944
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Debiopharm International SA·phase1·terminated·n = 19
AcromegalyGEP-NETDebio 4126Sandostatin LARSomatuline ATG
brief summary
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs).
started
May 18, 2022
primary completion
Oct 29, 2024
completion
Dec 3, 2024
last updated
Nov 17, 2025
official title
A Phase 1b Study in Patients With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) to Characterize the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Debio 4126, a 12-week Prolonged-release Octreotide Formulation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol